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Abstract 
This paper focuses on the positive impact of Real World Evidence (RWE) in Health 
Technology Assessment (HTA) submissions where price and reimbursement of drugs are 
informed. These last years, literature on RWE have proportionally increased with the 
phenomenon. Opinions in the literature and in pharmaceutical industries are mostly very 
enthusiastic; sometimes affirming that RWE could change a negative HTA decision into 
a positive one. Nevertheless, I doubt very much that RWE, a very new phenomenon, has 
a such strong impact. I’m sure RWE does make a positive impact on HTA decisions, but 
this impact seems to be restricted. This paper’s intention is to bring to the actual literature 
a more detailed picture of the true impact of RWE in HTA decisions. 
The development of this dissertation is based on two types of studies. The first one is a 
quantitative study on the acceptation of RWE in HTA decisions which objective is to 
analyse HTA submissions to understand how often RWE are refused and collect the 
reasons of their refusal. In the second study, I focus on three international cases where 
the reimbursement of a drug was first refused but, in re-submissions with an additional 
RWE, a positive reimbursement decision was given. The cases are the following: Yervoy 
in Australia HTA (PBAC), Zaltrap in Scotland (SMC) and Myozyme in France (HAS).  
The main findings of my research confirm that RWE is not overcoming Randomized 
Controlled Trials (RCTs). RWE is often refused in price and reimbursement submissions. 
Reasons expressed by HTA are all links to the lack of rigor of RWE. Nevertheless, the 
three case studies suggest that RWE has a stronger impact in re-submission when RCTs 
failed to bring evidences. Its impact has been confirmed in market access with Managed 
Entry Agreements (MEA), long-term follow up and in weak economic case. But its 
impact is restricted, in that the RWE never changed only by itself the HTA decision, but 
always in combination with a discount, an MEA or a RCT. While the role of RWE is very 
often described in the literature as a support to RCTs, I would rather conclude that its 
main impactful role is to fill the “evidence gap” when RCTs failed to bring it. 
Keywords: Real World Evidence (RWE), Health Technology Assessment (HTA), 
Randomized Controlled Trials (RCTs), Big Data, Zaltrap, Yervoy, Myozyme 
JEL Codes: H51; I18  
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Resumo 
Esta dissertação aborda o impacto positivo da Real World Evidence (RWE) nas 
submissões Health Technology Assesment (HTA), que contêm informações relativas ao 
preço e reembolso dos fármacos. Nos últimos anos, a literatura sobre RWE aumentou 
proporcionalmente ao fenómeno. As opiniões na literatura e na indústria farmacêutica são 
geralmente muito otimistas: por vezes, uma RWE pode reverter uma decisão negativa de 
uma HTA em decisão positiva. Todavia, duvida-se que a RWE, um fenómeno recente, 
possa ter um impacto tão forte. A RWE tem um impacto sobre as decisões de HTA, mas 
este impacto parece ser limitado. O objetivo desta dissertação é alargar o conhecimento 
da literatura atual com uma visão mais detalhada do impacto da RWE nas decisões das 
HTA. 
O desenvolvimento desta dissertação assenta em dois tipos de estudo. O primeiro é um 
estudo quantitativo sobre a aceitação da RWE pelas HTA; cuja metodologia possibilita 
analisar decisões HTA para avaliar com que frequência as RWE são rejeitadas e indicar 
as razões da rejeição. No segundo estudo, o foco incide sobre três casos internacionais 
onde o preço e reembolso dos fármacos foram inicialmente rejeitados, mas com nova 
submissão (“re-submissão”), e com uma RWE suplementar, foi dada uma decisão 
positiva de reembolso. Os casos escolhidos foram os seguintes: Yervoy na Austrália HTA 
(PBAC), Zaltrap na Escócia (SMC) e Myozyme na França (HAS). 
Os principais resultados do presente estudo confirmam que a RWE não supera os 
Randomized Controlled Trials (RCTs). A RWE é frequentemente rejeitada nas 
submissões de preços e reembolsos. As razões apresentadas pelas HTA apontam para 
uma falta de rigor da RWE. No entanto, os três casos sugerem que a RWE tem um impacto 
mais importante nas “re-submissões” quando os RCTs falham na obtenção de provas. O 
seu impacto foi confirmado no acesso ao Mercado com os Managed Entry Agreements 
(MEA), no longo prazo e em casos económicos fracos. No entanto, o seu impacto é 
sempre limitado, uma vez que a RWE nunca alterou por si só uma decisão da HTA, exceto 
em combinação com um desconto, um MEA ou um RCT. Ao passo que a função da RWE 
é frequentemente descrita na literatura como um apoio às RCTs, neste estudo conclui-se 
que a sua principal função é preencher a lacuna de provas quando o RCT foi ineficiente 
nesse sentido. 
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1. Introduction 
The last decades have seen huge advance and modification of data collection and use in 
our societies and the healthcare market hasn’t been an exception, big data reworked 
deeply the area. Many decisions are now driven by data, from the R&D of new molecules 
to the pharmacovigilance after the release of a drug. Traditionally, the RCTs 
(Randomized Controlled Trials) are granted as the highest collection data because they 
are designed to be unbiased and have less risk of systematic error (Burns et al, 2011). 
Nevertheless, even though RCTs remain the “gold standard” to obtain evidences, they 
have some limits. Indeed, the results are obtained in a highly controlled context and can 
be far from the reality. Innovation in technologies and the rise of Big Data enabled new 
ways of collecting data closer to the reality called Real World Evidence (RWE). In its 
Task Force Report of 2007, ISPOR described Real World Data as “data used for decision 
making that are not collected in conventional controlled randomized trials. While data are 
simply raw materials and alone are not informative, evidence is structured and aims to 
inform a conclusion or a judgment”. According to this definition, Real World Evidence 
is the common term used while approaching the subject, therefore it is the term employed 
in this paper. RWE appeared in the last decade and is becoming slowly a greater factor in 
decision-making, especially in Health Technology Assessment (HTA) submissions where 
price and reimbursement of drugs are informed. Nowadays a significant proportion of 
price and reimbursement submissions of new drugs are composed of RWE. 
These last years, literature and investigation on RWE have proportionally increased with 
the phenomenon. They are generally coming from institutions as the European 
Commission STAMP (Safe and Timely Access to Medicines for Patients) or the work of 
Garrison et al in the ISPOR Task Force (2007) which has been a good foundation for 
structuring this paper, indeed the International Society for Pharmaco-economics and 
Outcomes Research (ISPOR) is a great reference in health economics and outcomes 
research. Another important part of the literature found on RWE is coming from 
consulting companies of the area as IMSHealth or Deloitte. They have obviously, interest 
in telling how great RWE is, taking account, they are directly selling services linked to 
RWE. Articles found were very positive, assuring RWE could overtake RCTs. A glance 
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to some HTA decisions is nevertheless confirming the opposite, even though RWE 
represents a significant part of the evidences provided, it is always considered as a 
complement to RCT. Furthermore, many RWE are simply refused. Some other studies of 
RWE in HTA decisions exist but with very few case studies, and if they have, they are 
very light, describing in few lines the result of the price/reimbursement submission, and 
the RWE used: Harrison (2016) SVM Pharma report, IMS Brogan report (2013), Liden 
(2005) article in Pharmaphorum website. 
In this context, this paper aims at analyzing recent HTA submissions in order to determine 
its real added value. This paper claims to answer the following question: How Real World 
Evidence (RWE) can positively impact price and reimbursement of drugs? 
For answering this question the development of this dissertation is based on two types of 
studies. The first one is a quantitative study on the presence of RWE in HTA decisions 
and its acceptation. My hypothesis is that RWE is mainly refused because of its biased 
nature. The objective of this first study is to collect the reasons why RWE is often refused 
as evidence in HTA decisions. I decided to pick all submissions published on the French 
HTA website (HAS — Haute Autorité de Santé) of January 2017. The exclusion cases 
are the renewal submissions which are not interesting for our subject because of the 
reduced quantity of evidences needed and provided. Therefore, I include the inscriptions 
and revaluations of drugs.  
In the second study, I focus on three international cases where a drug was not initially 
recommended but, in re-submissions with the addition of RWE, a positive reimbursement 
decision was given. These three cases are based on an article from the Pharmaphorum 
website (2015). This restricted amount of illustrations aims at deeply analyze each of 
them by providing a substantial background information of the drug before a deep study 
of the structure and value of the RWE used. The aim is to make a link between the two 
studies and understand why RWE is often refused and why some RWE, unlike the others, 
are accepted and are making a positive difference. The HTA submissions and results are 
all public and available on the HTA national respective website.  
The rest of the study proceeds as follow: The second section reviews the literature by 
approaching the concept of RWE, its advantages and drawbacks compared to RCTs, and 
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its current uses. The third section explains the methodology of the quantitative RWE 
acceptation study and the three case studies, describing the criterion used for analyzing 
them. Section four is focused on the quantitative study of the French HTA decisions and 
RWE main reasons of refusal. Section five is dedicated to the case studies while the 
section six concludes this paper with suggestions on the future of RWE. 
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2. Real World Evidence (RWE) 
2.1 Relevant concepts 
2.1.1. Efficacy vs Effectiveness vs Efficiency 
The work of Cochrane in 1971 in his book ‘Random reflections on health services’ 
imposed the base of nowadays health care services and showed the need of distinguishing 
three different concepts: efficacy, effectiveness, efficiency. These terms are now pillars 
of health drugs assessment:  
Efficacy measures, in ideal circumstances, if the drug does more good than arm. It 
answers the following question: “Does it work?”  
Effectiveness is assessing if the drug works in real circumstances, ‘Does it work in real?’  
And finally, efficiency is counterbalancing results with the resources allocated ‘Does it 
worth it?’ 
Efficacy does not imply effectiveness. Let’s take as an example a drug with a very heavy 
treatment. The treatment requires ten injections per day and numerous pills. Injections 
and pills must be taken at very strict times; any differences of 15 minutes will decrease 
the effect of the drug by 50%. If all the criteria are respected, the drug is working perfectly 
and the illness will be stopped. On a clinical point of view, the efficacy of the drug is 
obvious but the effectiveness will be very low. In a clinical trial with a constant 
physician’s help and observation, patients will succeed to take fully the treatment. Back 
home and alone, patients won’t manage such a complex treatment.  
Effectiveness does not imply efficiency. Imagine a treatment for eczema implying three 
hospital visits per year; physicians apply a specific cream, too dangerous for patients to 
do it alone. The treatment works perfectly but its cost and the resources needed are far 
too high. Multiply the number of hospital visits by the people suffering of eczema, the 
capacity of today hospitals won’t be enough. The effectiveness of the treatment is proven 
but it is not efficiency.  
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2.1.2 RCTs & RWE: two different concepts 
A Randomized Control Trial (RCT) is “a trial in which subjects are randomly assigned to 
one of two groups: one, the experimental group, receiving the intervention that is being 
tested, and the other, the comparison group or control, receiving the conventional 
treatment” (Kendall, 2003). RCTs’ objective is to delete all possible bias in order to 
calculate the exact effect of an intervention. Sibbald (1998) in his paper “Understanding 
controlled trials: Why are randomized controlled trials important?” defines several 
important features that RCTs must respect to eliminate bias:  
• Patients are randomly assigned to the groups 
• Patients remain unaware of the assignment of the groups (Simple blinding) or 
patients and physicians remain unaware of the assignment of the groups (Double 
blinding) 
• All groups are treated equal except for the given treatment 
Randomization and blinding ensure that environment influence is reduced at its minima. 
Results are obtained in a highly controlled context, by nature RCTs are assessing efficacy. 
In opposition, Real World Evidence are evidences coming from data that are not collected 
in conventional Randomized Control Trials. Outside of this highly controlled context, 
RWE assess the drug in the “real world” measuring if the treatment is actually working 
in real condition, it is assessing effectiveness. 
Table 2.1: RCTs VS RWE distinct features 
 Randomized Control Trials Real World Evidence 
Answer the question Does it work?  Does it work in real?  
Primary Focus Efficacy, safety and quality Effectiveness 
Type of trial Experimental/Interventional Observational/Non-
interventional 
Circumstances Ideal circumstances Real circumstances 
Randomization 
&Blinding 
Yes No 
Monitoring Intense Not required 
Comparators Gold standard/Placebo None/Standard clinical 
practice 
Patient Population Narrow and Restricted Wide and Unrestricted 
Cost  €€€ € 
Source: “Demonstrating Value with Real World Data: A practical guide”, May 2011, Association of the 
British Pharmaceutical Industry (ABPI) 
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2.2.Innovation 
RWE is very new and its future is still unsure. Going through the literature there is a 
consensus to say RWE can be a big opportunity but its impact and role compared to 
RCTs is still unclear.  
According to Schumpeter, the "gale of creative destruction" in "Capitalism, Socialism 
and Democracy" in 1942 describes the "process of industrial mutation that incessantly 
revolutionizes the economic structure from within, incessantly destroying the old one, 
incessantly creating a new one". RWE is changing the structure of the pharmaceutical 
industry but unlike breakout innovation it is growing very slowly and its impact is 
unclear. It is not clearly “destroying the old one”.  
- Destruction creation: RWE overcome RCTS 
Some are very enthusiast and see RWE as the “new normal” (Sujay, 2017), “changing 
the game” (Thompson, 2017) “Investors […] need to think about how these companies 
will shift from clinical evidence development to real-world evidence development in 
order to yield the expected return on investment.”.  
- Destruction Mutation: RWE coexist in a complement way with RCTs 
While other think that “The traditional role for RWD is to support RCT data” (Jónsson, 
April 2017). 
“To evaluate the cost-efficiency of a drug in a real-world environment and gauge its 
impact on improving the quality of healthcare, RCTs need to be supplemented or 
followed up with the comparatively new standard, called real-world evidence (RWE).” 
(Saha et al, April 2015).  
A new set of technology (Computer, wearable technology, cloud etc) is making easier 
the share of data from the real world, transforming the pharmaceutical industry. 
Disruptive Innovation is described as the « Innovator Dilemma » by the professor 
Christensen; Disruptive technologies are "innovations that result in worse product 
performance, at least in the near term."  
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Actually, RWE is showing a great similarity to the innovator dilemma. RWE is not as 
better as RCTs. RCTs are still considered as the gold standard in the pharmaceutical 
industry but RWE could overtake it. 
 
It seems that RWE is a kind of innovation that is working in “Snowball effect”: “The 
concept of a large user base implies that the value of a product or a service increases as 
the number of users, together with complementary goods or services, increase.” 
(Goodman et al, 2013). Quantity is a key factor for the RWE network system works. 
More data are produced and exchanged, more evidences are available to prove drug’s 
efficacy or drug comparison. As a snowball, at the beginning the process is slow and 
then it is exponentially growing. 
2.3 RWE Typology 
2.3.1 Typology by data sources 
ISPOR, in its Task Force on Real World Data in coverage and payment decisions, sums 
up six Real World Data sources: 
(1) Supplement to RCTs, also called Piggyback because they are not the reason why 
the trial has been conducted, are additional information collected alongside the 
RCT. They are frequently health economic data as quality of life information. It 
is a convenient way to collect more data without conducting another study but as 
the initial trial was not made for the purpose of collecting these “second lines” 
data, the design of the RCT can be incompatible. One of the most frequent critics 
found in the literature, for example O'Sullivan et al, in 2005 in their paper 
“Collection of Health-Economic Data Alongside Clinical Trials: Is There a Future 
for Piggyback Evaluations?”, is that piggyback data are not Real World Data as 
they are collected in a “false environment”.  The behaviors of the patients can be 
far from the reality which is problematic since the objective of RWD is to get 
insights from the “real world”. 
 
(2) Practical Clinical Trials or Large Sample Trials are prospective studies with 
randomized assignment but with a bigger sample in a more heterogeneous 
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population (Tunis et al, 2003). The exclusion criteria are less strict, so the sample 
follows better the real-life settings. It is an efficient way to combine the data 
collection rigor of RCTs with the veracity of real world data. But, as the study is 
conducted in large sample and also in longer time it is very expensive. For 
example, the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial), is the largest hypertension clinical trial ever 
conducted: a sample of 42 418 patients (33 357 patients stayed on their study 
drugs until the end of the study) with a mean follow-up of 4.9 year has cost 120 
million dollars (Beevers, 2003). 
 
(3) Patient Registry is a “prospective method to collect uniform data (clinical and 
other) to evaluate specified outcomes for a population defined by a particular 
disease, condition, or exposure” (Gliklich et al, 2007). Patient registries can be 
conducted by a wide range of public or private institutions as government, non-
profit organization, hospitals, private company etc. For example, the Cystic 
Fibrosis Patient Registry has been created in 1966 and is collecting data on health 
outcomes, clinical care and demographic characteristics. It has nowadays data 
about 28,000 people with Cystic Fibrosis on decades (Cystic Fibrosis Foundation 
Website). 
 
(4) Claims databases are administrative data coming from health insurance 
programs and health care providers as bills. It is very useful data for knowing 
more on the quantity of care, their costs and reimbursements.  
 
(5) Health Surveys are good ways to obtain Patient Reported Outcomes. Patient 
Reported Outcomes (PROs) are defined as "any report of the status of a patient's 
health condition that comes directly from the patient, without interpretation of the 
patient's response by a clinician or anyone else."(US FDA, 2009). PROs can be 
collected by questionnaire or direct interviews. Commonly PROs questionnaires 
and interviews collect information as Quality of Life, symptoms, health 
perceptions, ratings of healthcare. 
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(6) Electronic health records (EHRs) and medical chart review. Electronic Health 
Record (EHR) is defined as “a longitudinal collection of electronic health 
information about individual patients and populations” (Gunter et al, 2005). The 
objective of EHR is to have a structured format to be easily shared with other 
Health care organizations. Each organization adding its own information, EHR 
contain information from all medical professionals involved in a patient’s care. 
While Patient Registries provide information on a specific population, EHR 
provides long term and global information. 
 
(7) These six main Real World Data sources are the most often used. Besides them, 
plenty of sources official or not can be used: Pharmacy data, Mortality Registries, 
Social Media, Consumer Data gathered through devices and health applications; 
Laboratories tests results, DNA Banks etc 
2.3.2 Typology by approach 
Real World Data is also often split into two groups: Retrospective and Prospective Data. 
Prospective and retrospective are two different angles a researcher can use for a study.   
Prospective study observes outcomes, such as the development of a disease, and relates 
this to other factors while retrospective study looks backwards and examines exposures 
to suspected risks in relation to an outcome that is established at the start of the study 
(Website “Stats Direct”). 
Figure 2.1: Prospective and Retrospective Studies 
 
Source: Text above 
Prospective Study 
Retrospective Study 
OutcomeExposure
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Table 2.2: Main differences between Retrospective and Prospective study 
Retrospective Prospective 
Looks backwards From present time to future 
The outcome has already happened by 
the time of study design (ex: 
pulmonary cancer) 
The outcome has not yet happened 
Can only be observational Can be observational or interventional 
Data already available Collection of data is necessary 
Source: Inspired by the table found in the Medical Biostatistics website; http://bit.ly/2v97l5t 
 
2.4 Advantages and drawbacks of RWE comparing to RCTs 
RWE shows some incontestable positive outcomes that are impossible or hard to get with 
RCTs. The ISPOR Task Force Report on RWE in payment decisions listed some of the 
benefits of this new kind of data: 
“Estimates of effectiveness rather than efficacy in a variety of typical practice 
settings” 
 
“Data in situations where it is not possible to conduct an RCT” 
In some situation, it is legally, ethically or physically impossible to conduct a RCT, for 
example in situation of narcotic abuse.  
“Information on how a product is dosed and applied in clinical practice and on levels 
of compliance and adherence to therapy” 
In RCTs patients are pre-selected according to the disease the searchers want to study. 
All patients receive a very exact number of drugs. Everything is controlled and nothing 
is being missed. In real life, patients can combine more than one disease, and so more 
than one treatment. For example, diabetes and cholesterol are often co-diseases. It is then 
important to verify than one treatment does not interfere with the other one.  
 
In real life patients can also have a lower adherence (whether the patient takes his 
treatment as prescribed) than in clinical trials. It is therefore important to check if the 
treatment is working with an adherence less than 100%. For example, a 95% of adherence 
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is requested for antiretroviral therapy against VIH to be effective (Basavaprabhu et al, 
2013). 
“Estimates of the evolving risk-benefit profile of a new intervention, including long-
term (and rare) clinical benefits and harms” 
While RCTs are done in a short time, RWE can ensure a lifelong follow-up, for example 
the Electronic Health Record or the Patient Registries.  For example, the Cystic Fibrosis 
Patient Registry has been created in 1966 and is collecting data on health outcomes, 
clinical care and demographic characteristics (Cystic Fibrosis Foundation Website). It has 
nowadays data about 28,000 people with Cystic Fibrosis on decades. Much more people 
or time than a RCT could do. As it is impossible to conduct a RCT on an entire human 
life, we never know the real risk of a drug on a human life. RWE can provide this kind of 
data and help to estimate the safety profile of each drug in long term. 
“Examination of clinical outcomes in a diverse study population that reflects the 
range and distribution of patients observed in clinical practice” 
RCTs are done in a small amount of people. RWE can be done in much bigger amount of 
people giving more strength to the results. 
“Results on a broader range of outcomes (well-being, quality of life), than have 
traditionally been collected in RCTs (major morbidity, short-term mortality)” 
Some outcomes as the well-being are hard to catch in RCTs. Patient Reported Outcomes 
(PROs) as questionnaires or interviews are essential for catching feelings and sensations.  
Additionally, in some disease, the survival rate doesn’t make sense; the Quality of Life is 
the main goal, for example the Atopic Dermatitis. The death rate is very low, but the 
disease burden is very high in term of quality of life. PROs provide essential information 
on the impact of this disease on people’s life.  
“Data in circumstances where there is an urgency to provide reimbursement for 
some therapies because it is the only therapy available and may be life-saving” 
Rare Diseases are very problematic in evidence generation as the range of people who 
can be selected for RCT is very narrow. “A disease or disorder is defined as rare in Europe 
when it affects less than 1 in 2000” (Rare Disease Day Organization Website). 
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Additionally, the high number of children in rare diseases is causing a problem as it is 
typically a sub-population excluded from RCT for ethical reason, “50% of rare diseases 
touch children” (Rare Disease Day Organization Website). 
 
 
RWE as Patient Registries can face better these limitations and complement RCTs in 
difficult situations. Gliklich in is article published in 2012 in the ISPOR Journal states 
that RWE as patient registries “are not a substitution for controlled trials. Instead, they 
serve as a valuable tool for researchers when determining if a trial is feasible and can 
complement a trial by providing data on product use, treatment patterns, and clinical 
questions about the disease that most likely do not already exist” RWE can help to fasten 
the gathering of evidence in situations where time is life-saving as no therapies exist. 
RWE is using a larger amount of heterogeneous people; it is a big advantage but also a 
drawback. Non-randomized selection exposes the study to bias and confounding (Saturni 
et al, 2014). Data collected from RWE sources is also more likely to be incomplete and 
of poorer quality. Indeed, they are mostly not collected for research purposed and the data 
extraction is not as controlled as in RCTs. Additionally, RWE is suffering of a lack of 
harmonization: Patient Registries, Electronic Health Records, Biobanks, Surveys, 
Interviews etc. RWE has a lot of sources in different format making it hard to structure. 
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Figure 2.2: Sum up of the advantages and drawbacks of RCTs and RWE 
 
Source: Sum up of info and sources above   
 
By looking at the pros and cons of each method, a clear complementarity appears. RCTs 
and RWE can be used together as Cox, 2013 suggested: “Each approach (RCTs, 
prospective observational and retrospective database studies) has unique strengths and 
weaknesses. By using a combination of these approaches and leveraging the ability to 
supplement any missing information with existing data from routine sources such as 
EHR, researchers can fill evidence gaps more efficiently and effectively.” RWE can also 
be a second step, as a confirmation of results found with RCTs as Saturni et al, 2014, is 
proposing “a workflow in which results from RCTs need to be confirmed by real life 
studies”. 
2.5 The present use of RWE 
The balance between RCTs and RWE swings from RCTs dominance at initial market 
authorization to a much greater use of RWE post-authorization (European Commission, 
2016). This shift follows the evidence need moving from efficacy-evidence at the drug 
development to effectiveness-evidence at price and reimbursement of the drug. 
Difficult to design 
and conduct 
(feasibility, 
expensive, ethical)
Cheap, larger 
number so more 
generalizable, 
longer follow-up, 
real settings
Provide strongest 
and most direct 
evidence for 
causality
Non-Randomized 
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bias/counfounding,  
less data quality,  
lack of 
harmonization 
RCTs 
RWE 
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Figure 2.3: Evidence needs evolves over time 
 
*PRA= Price Reimbursement Access 
Source: Cone et al, 2008, Regulation Reimbursement and Two sides of the same coin? 
Efficacy-Evidence 
Each drug goes through a regulatory submission for getting the Market Authorization. 
According to the online glossary of the World Health Organization (WHO) it is “an 
official document issued by the competent drug regulatory authority for the purpose of 
marketing or free distribution of a product after evaluation for safety, efficacy and 
quality”. As regulatory approval is based on efficacy, safety, and quality, at this step 
RCTs are the most appropriate methodology, showing if the drug works and does more 
good than harm in optimum conditions.  
Effectiveness-Evidence 
After getting the market authorization, drugs are assessed for price and reimbursement. 
Wide system differences exist between countries but in the last decades a tendency has 
been clearly identified: the growing role of the Health Technology Assessment (HTA). 
In contrast to regulatory approval, Health Technology Assessment examines the global 
impact of a drug.  
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According to the World Health Organization (WHO), HTA “refers to the systematic 
evaluation of properties, effects, and/or impacts of health technology. It is a 
multidisciplinary process to evaluate the social, economic, organizational and ethical 
issues of a health intervention or health technology. The main purpose of conducting an 
assessment is to inform a policy decision making.” 
These last decades, HTA systems spread worldwide and got a better structure. The 
International Network of Agencies for Health Technology Assessment (INAHTA) was 
created in 1993 and counts nowadays 55 member’s agencies from 32 countries (INAHTA 
website). There are wide differences of drug appraisal between each country, especially 
on the economic factors, nevertheless all HTA agencies are relying on the same pillar: 
the evidence-based decision. Every HTA recommendation is based on the evidences 
raised by the evaluation of the data provided on the drug. The correct use of data is crucial 
for a good assessment of the drugs, it is consequently advocated as one of their top 
missions: “All INAHTA members assess health technologies to support evidence based 
decision making in national or regional health systems” (INAHTA Website). 
Even though RCTs remain the gold standard in HTA decisions, nowadays a significant 
proportion of price and reimbursement submissions of new drugs are composed of RWE. 
At this time of the process, the efficacy of the drug is already proven. A good price and 
reimbursement is given to drugs showing a good effectiveness. With the rise of the 
technology, RWE is becoming enough trustful to show some evidences from the real 
world, especially in the Managed Entry Agreements. 
2.6 Managed Entry Agreements 
Traditionally, reimbursement decisions were limited to three options: Yes, No, Yes but 
with restrictions (ex: on a subgroup of patients, only if the first line drug didn’t work). 
With the increase of drug cost, higher control of the health expenses and the global 
uncertainty at drug launch, new reimbursement agreements have recently appeared. And 
RWE is nowadays a central part of these new agreements. 
At the time of making reimbursement decision, there is always a significant uncertainty. 
In some cases, this uncertainty is too big for allowing reimbursement. For example, a lack 
of effectiveness-evidence or a doubt on the budget impact for a drug. In these cases, HTA 
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can refuse the coverage, impose a reduce price/reimbursement or propose a more complex 
performance linked agreement called Managed Entry Agreements (MEA). It can also be 
called Risk-Sharing Agreements or Patient Access Schemes (PAS).  
MEA can reduce uncertainty by sharing the risks of a drug launch. A Managed Entry 
Agreement is “an arrangement between a manufacturer and payer/provider that enables 
access to (coverage/reimbursement of) a health technology subject to specified 
conditions. These arrangements can use a variety of mechanisms to address uncertainty 
about the performance of technologies or to manage the adoption of technologies in order 
to maximize effective their use, or limit their budget impact” (Carlson et al, 2010). 
A wide variety of MEA exist, here are some examples:  
- Initial free product and then reimbursement given if the effectiveness is shown 
-If performance is lower than predicted by the manufacturer, he will provide a discount 
to the payer 
-The manufacturer will reimburse the payer the doses of patients who did not respond to 
the therapy 
- If a bigger quantity of drug doses is sold, the excess doses will be given for free by the 
manufacturer 
When the MEA is based on the performance of the drugs, as the three first examples, Real 
World Evidence is a central piece of the agreement. It will prove the real performance of 
the drug and therefore trigger a reimbursement or a discount. For example, Patient 
Registries can be conducted after the release of the drug on the market and a discount 
from the manufacturer to the payer is given if, after 2 years, performance objective is not 
achieved.  
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3. Methodology 
3.1 Objective 
The strategy of this paper is divided into two studies, one quantitative, one qualitative. 
The first study focuses on how RWE is accepted in the HTA recommendations. A quick 
look on the HTA decisions showed that RWE is very often refused. Therefore, the study’s 
objective is to study the reasons why RWE is often refused. 
The second study is a study of three successful cases where RWE has been the crucial 
element that changed the HTA decision from a refusal to an agreement. The aim is to 
make a link between the two studies and understand why RWE is often refused and why 
some RWE, unlike the others, are accepted and are making the positive differences. 
3.2 Selection Criteria and methodology 
One of the limits of this paper is the lack of information. Data on drug HTA assessment 
is available on each HTA country website but data quantity and quality differs a lot 
between each country. For this first study, the data selected are coming from the French 
HTA Haute Autorité de Santé (HAS). Unlike Portugal, Germany or Italy HTA, HAS is 
giving a very consistent report for each drug’s assessment and very often in English. The 
selection is focus on the drug’s assessment published in the HAS website in the month of 
January. Reregistration of drugs are excluded. The study includes 25 drug’s assessments. 
On the 25 assessments, the cases containing RWE are going to be studied deeper to find 
if the RWE used have been accepted. And if they have been refused, which reasons 
justified the refusal. 
For the second study, the three cases selected are based on the article “Does real world 
evidence matter in Health Technology Assessments?” written by Linden et al, 2015, in 
the website Pharmaphorum. The three cases are cases “where a drug was not initially 
recommended but, in re-submissions with the addition of RWE, a positive reimbursement 
decision was given.” This selection criteria permit to identify the impact of the RWE 
besides the RCTs. The cases are the following: Yervoy in Australia HTA (PBAC), Zaltrap 
in Scotland HTA (SMC) and Myozyme in French HTA (HAS). The article is giving a 
brief overview of the cases. The aim of this paper is to go far deeper in the HTA decisions. 
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3.3 Collection of Data 
All the HTA submissions and decisions are published in their websites, here is the list 
and the website link to the HTA included in my studies: 
- France: HAS – Haute Autorité de Santé 
http://bit.ly/2jjpdVn 
-Scotland: SMC - Scottish Medicines Consortium 
http://bit.ly/2tF4mmW 
 
-Australia: PBAC – Pharmaceutical Benefits Advisory Committee 
http://bit.ly/2tHWnW4 
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4. Quantitative Study on RWE acceptation 
A quick look to the HTA decisions showed that they often refuse RWE. This first study 
aims to verify this hypothesis and then analyse the reasons of HTA when they refuse a 
RWE in a submission. To the best of my knowledge there are no studies in the literature 
collecting the reasons why an HTA refused a RWE.    
The first step of the study was to collect decisions of the French HTA (HAS) in the month 
of January 2017 (Table 4.1). The column “Decision” refers to the decision of 
reimbursement. Refused means that the drug won’t be registered on the reimbursement 
list.  
Most of submissions studied were inscription which means it was the first submission of 
the manufacturer for this drug. Revaluation is when the manufacturer asks the HTA to 
revaluate new pieces of evidence to get a better reimbursement and potential good price. 
In blue, the submissions including RWE which are studied deeper in the table 4.2.  
Table 4.1: HAS Decisions in January 2017 
 
Source: HAS Website http://bit.ly/2jjpdVn 
Drug Indication Company Date Type Decision RWE
Misodel Pregnancy Ferring 14/12/2016 Inscription Refused YES
Pradaxa Anticoagulant B-I 14/12/2016 Revaluation No modification YES
Orfadin Orphan Disease Biovitrum 14/12/2016 Inscription Accepted NO
Monover Hematology Medipha 14/12/2016 Inscription Accepted YES
Champix Smoking Addiction Pfizer 09/11/2016 Inscription Accepted YES
Jardiance Diabetes B-I 19/10/2016 Revaluation No modification YES
Briviact Epilepsy UCB Pharma 20/07/16 Inscription Accepted NO
Paracetamol Painkiller Mylan Pharma 11/01/2017 Inscription Accepted NO
Pixuvri Hematology Servier 13/01/17 Revaluation No modification YES
Likozam Psychiatry Advicernne 13/01/17 Inscription Accepted YES
Lixiana Anticoagulant cerebrovascular stroke Daiichi Sankyo 13/01/17 Inscription Accepted YES
Lixiana Anticoagulant Thrombosis/Embolism Daiichi Sankyo 06/07/2016 Inscription Accepted YES
Xarelto Anticoagulant Bayer 11/05/2016 Revaluation Accepted YES
Holoclar Stem cell Chiesi 20/07/2016 Inscription Accepted YES
Domperidone Nauseaet and Vomiting Biogaran 11/01/2017 Inscription Both, depends on the indication NO
Bosentan Hypertension Accord 11/01/2017 Inscription Accepted NO
Bosentan Hypertension Teva 11/01/2017 Inscription Accepted NO
Bosentan Hypertension Mylan Pharma 11/01/2017 Inscription Accepted NO
Entresto Heart Failure Novartis 11/01/2017 Revaluation No modification YES
Domperidone Nauseaet and Vomiting Biogaran 11/01/2017 Inscription Accepted NO
Domperidone Nauseaet and Vomiting Teva 11/01/2017 Inscription Accepted NO
Mikicort Corticoids Mayoly Splinder 11/01/2017 Inscription Accepted NO
Taltz Psoriasis Lilly 05/10/2016 Inscription Accepted NO
Pottassium H2 Supplement H2 25/01/2017 Inscription Accepted NO
Cimzia Rheumatism UCB Pharma 11/01/2017 Inscription Refused NO
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General Statistics  
General statistics show first that almost one on two submissions contains RWE, 48% of 
submissions has at list one RWE. 
Figure 4.1: Percentage of submissions with RWE 
 
 
 
 
 
Source: Table 4.1 
 
Statistically submissions with RWE obtain more refusal than RCTs, 5 on 12 submissions 
against 2 on 14 for submissions with RCTs. 
 
Figure 4.2: Proportion of submissions accepted or refused per the presence of RWE 
 
Source: table 4.1 
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These two results demonstrate that the use of RWE is largely common among the 
pharmaceutical companies. Nevertheless, it is less accepted in HTA, in our case the 
French one, HAS. This can be explained by the role of the RCTs which still represent the 
“golden standard” of the evidence in drugs evaluation. RWE is a new concept which 
utilization is gradual in time. It is acceptable than public authorities show some limitations 
and doubts to use RWE.  
Focus on submissions with RWE 
The second step of the study is to analyse deeper the submissions including RWE from 
the table 4.1. The following table shows which kind of RWE were used in the 
submissions. It also shows if the RWE were accepted by the HTA and if not, which 
reasons the HTA mentioned to argue the refusal (last column “Reason”). 
Table 4.2: Cases from Table 1 with RWE 
 
 
 
 
 
 
 
 
 
 
 
 
Source: HAS Website http://bit.ly/2jjpdVn 
Drug Category RWE Type Acceptation Reason
Doesn't study the right population
The periods of study are different for the two 
compared drugs
Bias of recommendation
Selection of the patient files not well described
Tolerance PSUR Periodic Safety Update Report YES
The statistical power of the study is too weak to 
detect light risk increase
Short term study
Lack of data on confusion factors
Overestimation of some results
American data with different dose and indication
Lack of data
Short term study, possible underestimation of 
risk
Efficacy/Tolerance
Retrospective Cohort with national New-Zealand data from the 
NMDS (National Minimum Dataset) and Pharmaceutical 
Partially Lack of data on confusion factors
Tolerance National data of Pharmacovigilance 1 YES
Tolerance National data of Pharmacovigilance 2 YES
Tolerance International data of pharmacovigilance Partially Bias that could affect results
Monover Tolerance International data of pharmacovigilance YES
Tolerance 7 cohort studies YES
Tolerance National data of Pharmacovigilance YES
Tolerance Data of utilization and recommendation from IMS-EPPM NO
Not enough quantity of recommendations for an 
analyze
Jardiance Tolerance International data of pharmacovigilance YES
Pixuvri Efficacy retrospective study NO
The efficacy data are note available for the right 
indication
Likozam Tolerance Expanded Access Data YES
Tolerance International data of pharmacovigilance YES
Efficacy/Tolerance Open extension study NO Too many patients dropped the study
Lixiana Tolerance International data of pharmacovigilance YES
Xarelto Tolerance National data of Pharmacovigilance YES
Short term study
Not enough patients
High variability of the results
Entresto Efficacy/Tolerance Expanded Access Data
NO Efficacy 
YES Tolerance
Partially
Efficacy/Tolerance Retrospective Cohort with data from the Quebec Social Security Partially
Champix
Lixiana 
Misodel
Efficacy/Tolerance Retrospective cohort from hospital patient files
NO Efficacy 
YES Tolerance
Pradaxa
Efficacy/Tolerance
Retrospective cohort with data from SNII-RAM (Social Security 
data) and PMSI (Data management system)
Partially
Efficacy/Tolerance
Retrospective cohort with data from Medicare and Truven Health 
Marketscan Commercial Claims and Encounters
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On the 25 submissions, 12 include RWE. Data on Holoclar’s evaluation have been 
removed as this is not a typical drug but an eye transplantation it is then impossible to 
conduct a RCT as randomization and placebo is not possible. This paper’s aim is to study 
the importance of RWE compared to RCTs, the case of Holoclar doesn’t fit the criteria. 
11 cases with RWE have been kept. The RWE provided are the following: 
- 12 Cohort Studies from which 5 are retrospective. The retrospective cohorts are based 
on hospitals, national files and social security data as the Quebec Social Security Data, 
Medicare or New-Zealand data from the NMDS (National Minimum Dataset). 
- 9 National & International data of Pharmacovigilance 
-3 Expanded Access Data 
- 1 Data of utilization and recommendations 
-1 observational retrospective study 
-1 Expansion study 
On the 27 RWE provided, 14 are given to only prove the good tolerance of the drug and 
2 of them the good efficacy. 5 are given to prove both efficacy and tolerance. And two 
cases, Misodel and Entresto, have one RWE which is given to prove efficacy and 
tolerance but studied separately. 
Table 4.3: Acceptation of the RWE according to the Efficacy and Tolerance category of 
evidence 
 Accepted Refused Partially* Total 
Efficacy 0 1 0 1 
Tolerance 17 1 1 19 
Efficacy/Tolerance 0 1 4 5 
Total 17 3 5 25** 
Source: Table 4.2 
*Partially accepted means that the HAS took the evidence in consideration but some fundamental limits 
to the evidence are existing  
**The result doesn’t count the Misodel and Entresto specific case, described below 
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Table 4.4: Misodel and Entresto specific cases 
Drug RWE Category of evidence Acceptation 
Misodel 
Retrospective cohort from 
hospital patient files 
Efficacy NO 
Tolerance YES 
Entresto Expanded Access Data 
Efficacy NO 
Tolerance YES 
Source: Table 4.2 
The table 4.3 show that most RWE are accepted in the evaluation of the HTA, 17 on 25.  
But a closer look demonstrate that this result is totally different when comparing the score 
of acceptance by tolerance and efficacy. The 17 RWE accepted were all used to prove the 
tolerance of the drug. The unique RWE used to prove the efficacy of the drug was refused. 
And the 5 RWE proving both tolerance and efficacy were refused in one case and partially 
in the 4 others. 
Numbers are clearly demonstrating that RWE are accepted to prove tolerance but not 
efficacy. It is even more distinct in the table 4.4; in the case of Misodel and Entresto, the 
RWE used to prove both efficacy and tolerance. They were accepted for the evaluation 
of tolerance but refused for efficacy.  
On the 10 RWE refused or partially accepted, the reasons can be sorted into three groups: 
 
Problem of Focus 
• The study is not focusing on the population related to the drug inscription (2 times) 
• The period of study is different for the two compared drugs  
• Transposition impossible, the data come from USA where the doses and 
recommendations are different compared to France 
Lack of information 
• Selection of the patient files not well described 
• Lack of data (3 times) 
• Not enough elements for an analyse 
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• Not enough patients/Too many patients dropped the study 
Modification of the results 
• Bias are existing in the study (2 times) 
• The statistical power of the study is too weak to detect light risk increase 
• The term of the study is too short (2 times) 
• High variability of the results 
• Overestimation of the results  
 
Conclusion of the results 
Results clearly show that RWE is not overcoming RCTs. While RWE is accepted when 
proving tolerance, it is mainly refused when proving the efficacy of a drug. The reasons 
mentioned by the HTA to explain the refusal are all linked to the lack of rigor of RWE: 
-The problem of focus can be explained by the fact that RWE is suffering of a lack of 
harmonization: Patient Registries, Electronic Health Records, biobanks, Surveys, 
Interviews etc. RWE has a lot of sources in different format making it hard to structure. 
-The lack of information can be explained by the fact that RWE is mostly not collected 
for research purposed and the data extraction is not as controlled as in RCTs. So, it is 
more likely to be incomplete and of poorer quality. 
-The modification of the results can be explained by the fact that RWE is using a larger 
amount of heterogeneous people and is not randomized which expose the study to bias 
and confounding.  
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5. Case studies 
5.1. Introduction 
The three cases selected are based on the article “Does real world evidence matter in 
Health Technology Assessments?” from Liden et al, January 2015 in the website 
Pharmaphorum. The three cases are cases “where a drug was not initially recommended 
but, in re-submissions with the addition of RWE, a positive reimbursement decision was 
given”. This selection criteria allows to identify the impact of the RWE besides the RCTs.  
The cases are the following: Yervoy in Australia HTA (PBAC), Zaltrap in Scotland HTA 
(SMC) and Myozyme in French HTA (HAS). While the article is giving a very brief 
overview of the cases, the aim of this paper is to go far deeper in the HTA decisions. 
HTA systems are different among the world. Australian HTA, PBAC, and Scottish HTA, 
SMC, are both basing their recommendations on a clinical and economic evaluation. The 
economic evaluation is in both HTA based on the Quality Adjusted Life Year (QALY) 
system described in the following pages in the section 5.2.1. While the French HTA, 
HAS, has a different system based on the admitted level of the Medical Benefit (SMR- 
Service Médical Rendu) and Improvement of Medical Benefit (ASMR- Amélioration du 
Service Médical Rendu) explained in the section 5.2.2. 
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Table 5.1: Main info on the three cases chosen 
 Case 1 Case 2 Case 3 
Brand Name/INN* Yervoy/Ipilimumab Zaltrap/Aflibercept 
Myozyme/ 
Alglucosidase Alfa 
HTA PBAC SMC HAS 
Country Australia Scotland France 
Number of Re-submission 2 1 3 
Causes of Refusal 
Uncertain extent of clinical 
benefit, uncertain clinical 
place of therapy, high and 
uncertain cost-
effectiveness ratio and 
uncertain financial costs 
Weakness of the economic 
case 
Not enough data on the 
effectiveness of the drug 
RWE used 
Periodic Safety Update 
Report & data from Patient 
Access Programs 
Two on-going, open-label, 
single-arm studies 
Observationnal studies, 
Pompe disease registry 
Discount provided YES YES Unknown 
Managed Entry Agreements 
Cost-effectiveness or 
budget impact 
Unknown  Unknown 
Source: All the information from this table have been found in the website of PBAC, SMC and HAS  
- France: HAS – Haute Autorité de Santé 
http://bit.ly/2jjpdVn 
-Scotland: SMC - Scottish Medicines Consortium 
http://bit.ly/2tF4mmW 
-Australia: PBAC – Pharmaceutical Benefits Advisory Committee 
http://bit.ly/2tHWnW4 
 
*International Nonproprietary Name 
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5.2. Systems of evaluation 
5.2.1. The QALY system  
QALY stands for Quality Adjusted Life Year. “It is a tool used in health economics 
evaluation to quantify the health effect of a medical intervention” (Lieven, 2017). A 
QALY considers how a treatment affects a patient’s quantity of life and quality of life. 
The quality of life is indicated on a range between 1 and 0; 1 is the maximum and means 
perfect health and 0 is the minimum and means death. The calculation is the following: 
Years of Life x Quality of Life = QALYs 
Considering the calculation, here are some example:  
• A person who lives one year in perfect health will have 1 QALY: 
1 Year of Life × 1 Perfect Quality of Life = 1 QALY 
• A person who lives only for half a year but in perfect health will have 0.5 QALYs: 
0.5 Years of Life x 1 Perfect Quality of Life = 0.5 QALYs 
•In the same logic, if a person lives for one year in a situation with half of perfect health, 
that person will also have 0.5 QALYs:  
1 Year of Life x 0.5 Medium Quality of Life = 0.5 QALYs 
QALYs is used to measure and compare the cost-effectiveness of each medicine. States 
have a limited amount of budget, they can’t pay for all drugs. The QALYs is a tool which 
help to take decisions on which medicine would contribute the most to the well-being of 
the society taking into consideration the cost and the benefits of each drug.  
This system is used by several countries for drug assessment and price and reimbursement 
settings as Scotland or Australia which are respectively our first and second cases. 
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5.2.2. The SMR/ASMR system 
The SMR/ASMR is a unique system only used in France.  
For each submission the French HTA, HAS, takes into consideration all the evidences on 
the drugs and informs the admitted level of the Medical Benefit (SMR- Service Médical 
Rendu) and the admitted level Improvement of Medical Benefit (ASMR- Amélioration 
du Service Médical Rendu) (Chicoye et al, 2009).  
SMR and ASMR can be seen as two ladders of marks. 
The SMR has four levels and shows the importance of the medical benefit of the drug: 
insufficient, weak, moderate or important. It determines the stage of reimbursement: 15% 
for a weak SMR, 30% for moderate and 65% for important (HAS Website, Évaluation 
des médicaments en vue de leur remboursement, 2015). 
The ASMR is a crucial element for the determination of the price. It has 5 levels: 
•Level I, Major innovation  
•Level II, Important improvement  
•Level III, Significant improvement  
•Level IV, Minor improvement  
•Level V, No improvement 
The price of the drug will be partially determined by the ASMR level.  
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5.3. Cases studied 
5.3.1. Yervoy (Australia) 
5.3.1.1. Drug Details 
Brand Name/ International Non-proprietary Name(INN): Yervoy/Ipilimumab 
Category: Malignant Melanoma (Skin Cancer) 
Submission: July 2011 
Reason of refusal: uncertain extent of clinical benefit, 
uncertain clinical place of therapy, high and uncertain 
cost-effectiveness ratio and uncertain financial costs 
Re-Submission: March 2012 
Re-submission n°2: November 2012 
HTA: Pharmaceutical Benefits Advisory Committee 
(PBAC) 
Manufacturer: Bristol-Myers Squibb  
The information for this case study have been found in the public reports provided by the 
PBAC in their website. The reports are available from: 
• Submission:http://www.pbs.gov.au/info/industry/listing/elements/pbac-
meetings/psd/2011-07/pbac-psd-ipilimumab-july11 
• Re-submission n°1:http://www.pbs.gov.au/info/industry/listing/elements/pbac-
meetings/psd/2012-03/ipilimumab 
• Re-submission n°2: http://www.pbs.gov.au/info/industry/listing/elements/pbac-
meetings/psd/2012-11/ipilimumab 
According to the Dermatology Information System DermIS the malignant melanoma is 
“the most aggressive and life-threatening skin cancer. It develops in the cells that give the 
skin its color (melanocytes) and has a very high tendency to spread to other parts of the 
body”. 
Source : https://www.ilmelanoma.com/en/melanoma/m 
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According to the PBAC, advanced melanoma “has a median survival of approximately 6 
to 9 months”. The strongest environmental risk factor in the development of melanoma 
is the exposure to strong solar UV radiation. Australia has the highest incidence of 
advanced melanoma per population in the world due to a very strong solar situation and 
a high presence of Caucasian population. 
Ipilimumab is a treatment for patients with a such advanced stage of malignant melanoma 
that surgery is impossible, and who were not responsive or were intolerant to prior 
therapy. 
5.3.1.2. Clinical Analysis 
The submission presented a randomised double-blind, multicentre trial subjects with 
advanced stage of melanoma, impossible to operate, and who were not responsive or 
unable to tolerate at least one or more previous treatments. The result of the study was a 
reduction in hazard of death of 34% in the ipilimumab monotherapy group compared to 
the control group. The median survival for the ipilimumab monotherapy arm was 10.12 
months compared to 6.44 months in the control group. The PBAC noted that the median 
difference in survival was approximately 3.6 months. The PBAC considered these results 
were “uncertain and difficult to interpret due to the low number of patients remaining in 
the study”. Especially because ipilumimab treatment is very heavy; some patients had to 
stop the study because of adverse events.  “Approximately 62% of patients in the 
ipilimumab monotherapy group compared to 32% of patients in the control group 
experienced an Immune Related Adverse Events (irAE)” according to the PBAC report. 
This represents a statistically significant difference. 
5.3.1.3. Economic Analysis 
The base case incremental cost per QALY gained was between $105,000 and $200,000 
and the estimated financial cost to the PBS was considered to be between $30-60 million 
in Year 5. 
5.3.1.4. Recommendation 
The PBAC acknowledged that there was “a high clinical need for a drug to treat metastatic 
melanoma as there are few other viable options for patients with this condition”. 
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The submission described ipilimumab as “superior in terms of comparative effectiveness” 
but the PBAC considered this claim may not be reasonable as ipilimumab may be 
considered “inferior in terms of immune related adverse events”. Moreover, a recent 
publication showed an incremental benefit of 2.1 months. The PBAC therefore concluded 
that the 3.6 months survival gain was an overestimate. 
The PBAC considered that the costs associated with the treatment adverse drug effects 
were considerably underestimated as there may be more inpatient hospital cost as well as 
greater costs associated with the PBS subsidised treatment of adverse events.  
There is also potential for use in the first-line setting, even if the listing mandates failure 
of a first line systemic therapy. Physicians still have the freedom to use the drug in first 
line. The consequence will be an increase of the budget allocated to this treatment. 
The PBAC therefore refused the reimbursement because of an “uncertain extent of 
clinical benefit, uncertain clinical place of therapy, high and uncertain cost-
effectiveness ratio and uncertain financial costs.” 
5.3.1.5. Re-Submission 
In the first re-submission, there were no additional evidences but additional exploratory 
analyses relating to the safety profiles of ipilimumab. The resubmission claimed that early 
management of irAEs can minimise their impact. The company also proposed a reduce 
price but the PBAC did not change its decision. 
 
In the second re-submission, a new discount was proposed; the new proposed cost was 
$45,000 - $75,000 per QALY. The global estimated budget of the PBAC increased to 
more than $100 in year 5 including because of the acceptation of the PBAC to authorize 
the treatment in first line if needed. 
There were no new comparative clinical data but several new clinical trials related to the 
durability of the drug: 
• Five-year follow-up from ipilimumab clinical trials 
• Four-year follow-up from ipilimumab clinical trial 
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• Long-term (five years and greater) follow-up from 177 metastatic melanoma 
patients treated with ipilimumab 
• The resubmission cited two additional papers outlining existing longer-term 
follow-up than five years 
• An expert statement related to ipilimumab and durability. 
And three RWE: 
• The most recent Periodic Safety Update Report (PSUR) 
• Italian ‘real-world’ data relating to efficacy, safety, and rates of re-induction from 
the European Expanded Access Programme (EAP) and submitted to the European 
Society for Medical Oncology (ESMO) conference in October 2012 
• Australian ‘real-world’ data resulting from the Patient Access Program (which 
existed between the 1st August 2011 and the 15th April 2012) 
The new pieces of evidence confirmed the durability of the clinical effect. The PBAC 
agreed that the results from the European Expanded Access Programme (EAP) in Italy 
supported the results seen in the other trials mentioned above. Additionally, new toxicity 
data from the latest Periodic Safety Update Report (PSUR) did not identify any new safety 
concerns. No further comments have been made on the role of the RWE. 
5.3.1.6. Managed Entry Agreements 
The PBAC considered that the new proposed cost of $45,000 - $75,000 per QALY was 
“high but acceptable if the modelled survival gain is observed in clinical practice”. In the 
last submissions, the uncertainty of the clinical benefit, of the place of the therapy and of 
the financial costs pushed the PBAC to refuse the treatment. The PBAC is now proposing 
two different MEA to reduce the risks and costs:  
- The implementation of “a mechanism to verify the anticipated overall survival benefits 
of ipilimumab in real world clinical practice in Australia”. This mechanism should be 
done in a way that it gives evidences of “whether or not the extent of the survival benefit 
presented in the submission and which was used in the calculation of cost-effectiveness, 
was realised in Australian clinical practice”. The company would have to reimburse the 
33 
 
cost of difference in performance between the observed benefits and the benefits 
promised in submission.   
- “Negotiation of significant rebates in terms of number of patients and dose”. Which 
means that the company will offer the additional treatments if the number of patients 
treated has been overwhelmed. This negotiation aims to control the budget decided by the 
PBAC for this treatment which is over $100 million in Year 5. 
The final MEA chosen remain non-public. In both cases, RWE will be collected to 
measure the impact of the treatment and to calculate the rebates that the company will 
give to the Australian healthcare system. 
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Source : http://www.zaltrap.com  
5.3.2. Zaltrap (Scotland) 
5.3.2.1. Drug Details 
Brand Name/INN: Zaltrap/Aflibercept 
Category: colorectal Cancer 
Submission: 7 June 2013 
Reason of Refusal: Weakness of the economic case 
Re-Submission: 7 February 2014 
HTA: Scottish Medicines Consortium (SMC)  
Manufacturer: Sanofi-Aventis 
 
The information for this case study have been found in the public reports provided by the 
SMC in their website. The reports are available from: 
• Submission: 
https://www.scottishmedicines.org.uk/SMC_Advice/Advice/878_13_aflibercept
_Zaltrap/aflibercept_Zaltrap 
• Re-submission: 
https://www.scottishmedicines.org.uk/SMC_Advice/Advice/878_13_aflibercept
_Zaltrap/aflibercept_Zaltrap_Resubmission 
Aflibercept is a treatment for metastatic colorectal cancer. Metastatic colorectal cancer is 
cancer of the large bowel and rectum that has spread to other parts of the body. Aflibercept 
is given as an intravenous infusion over one hour every 2 weeks. It is given in combination 
with other chemotherapy. 
5.3.2.2. Clinical Analysis 
The original submission contains one evidence; a randomised, placebo-controlled study. 
The primary endpoint was overall survival. Results of the study show that the median 
overall survival was significantly longer for aflibercept than placebo. 
The secondary endpoints included progression free survival (PFS) and response rate. The 
progression free survival is defined by the National Cancer Institute as “the length of time 
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during and after the treatment of a disease, such as cancer, that patient lives with the 
disease but it does not get worse”. The PFS and response rate were both significantly 
higher for the aflibercept group than placebo. Better results are confirmed in some 
subgroups of patients, for example, patients with liver metastases. 
In brief, the RCT showed a significant longer median overall survival. Results of the 
secondary endpoints were supportive of the primary endpoint. The comparator used and 
the study inclusion criteria were appropriate. But there are some limitations in the study 
results and design, the major ones are described below. 
Even though the median overall survival is higher among patients treated with aflibercept, 
the additional median survival of 1.44 months is a modest result. Furthermore, there is no 
data on quality of life. 
The treatment with aflibercept require an additional infusion of one-hour duration which 
means additional costs and services. Moreover, the combination of aflibercept to other 
chemotherapy was associated with significant adverse events that were not always 
manageable clinically, and forced some patients to stop the treatment. 
5.3.2.3. Economic Analysis 
The original cost per QALY is not communicated. Data published concerned the cost per 
QALY with the inclusion of a discount proposed by Sanofi. The treatment offers a 0.2429 
QALY gain, for an incremental cost of £8,816 which is equivalent to the amount of 
£36,294 for one QALY. 
For the subgroup of patients with liver metastases the cost per QALY was estimated to 
be £30,474 with the discount for an incremental cost of £10,974 and a QALY gain of 
0.3601.  
The difference in overall survival is statistically significant in the calculation. A better 
result in overall survival, like an increase by 30%, would have reduce the cost per QALY 
to 28.5K. The additional cost of the aflibercept treatment was not included in the QALY 
calculation.  
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5.3.2.4. Recommendation 
The reimbursement of aflibercept was refused because the “economic case has not 
been demonstrated”, indeed the high cost per QALY and the weaknesses outlined 
above didn’t convince the SMC. 
5.3.2.5. Re-submission 
In the re-submission, the company provided a deeper analysis of the randomised 
controlled study showed in the submission and, above all, two RWE. Two on-going, 
open-label, single-arm studies aiming to assess the safety and quality of life of the 
aflibercept treatment. The inclusion and exclusion criteria were similar to the randomised 
controlled study. Five dimensions were included in the study (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression) and then converted into a single index 
utility score (minimum value of -0.594 and a maximum value of 1.0). At baseline the 
mean of the utility score was 0.77 and at cycle three it was 0.78. At cycle five the utility 
score was 0.79. The utility score showed that the quality of life under the treatment is 
overall good, and remain stable.  
A revised discount was submitted by the company and accepted. With the discount, the 
submitting company estimated a cost per QALY of £34,623 based on an incremental cost 
of £8,519 and a QALY gain of 0.2460. For the subgroup of patients with liver metastases 
the cost per QALY was estimated at £27,424 based on an incremental cost of £10,164 
and a QALY gain 0.3706. 
Table 5.2: QALY gain and cost difference between the submission and the resubmission 
 Submission Resubmission 
 Overall Subgroup Overall Subgroup 
QALY gain 0.2429 0.3601 0.2460 0.3706 
Incremental Cost £ 8,816 10,974 8,519 10,164 
Cost per QALY £ 36,294 30,474 34,623 27,424 
Source: Public reports of the submission and re-submission, available in SMC Website and quoted above 
In the resubmission, the QALY gain slightly increased, especially thanks to the two open 
studies which proved a stable quality of life under the treatment. Additionally, the 
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incremental cost decreased because of a bigger discount from the company. In 
consequence, the cost per QALY decreased. But the SMC announced that this decrease 
is largely due to the increase of the discount. 
The SMC affirms that it does not have a formal threshold cost per QALY below which 
cost-effectiveness would be considered demonstrated. When the cost per QALY is high, 
other factors can also play a role in SMC’s assessment and may change the final decision.  
These factors are listed in the SMC website and are the following: 
- “Evidence of a substantial improvement in life expectancy with a sufficient quality of 
life to make the extra survival desirable. Substantial improvement in life expectancy 
would normally be a median gain of 3 months. 
-Evidence of a substantial improvement in quality of life (with or without survival 
benefit); 
-Evidence that a sub-group of patients may derive specific or extra benefit and that the 
medicine in question can, in practice, be targeted at this sub-group; 
-Absence of other therapeutic options of proven benefit for the disease in question  
-Possible bridging to another definitive therapy in a defined proportion of patients;” 
In the Zaltrap case, the SMC agreed that the criteria of a substantial improvement in 
quality of life in the patient population targeted in the submission was satisfied and there 
being a subgroup of patients who may derive specific or extra benefit were satisfied. 
Therefore, the high cost per QALY is considered acceptable given the reasons 
described just above. 
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5.3.3. Myozyme (France) 
5.3.3.1. Drug Details 
Brand Name/ International Non-proprietary Name (INN): Myozyme/ Alglucosidase 
Alfa 
Category: Pompe disease 
Submission: September 2006 
Reason of refusal: Lack of data on effectiveness 
Re-submission: June 2010 
Re-submission: January 2013 
Re-submission: March 2017 
HTA: Haute Autorité de Santé (HAS) 
Manufacturer: Genzyme  
The information for this case study have been found in the public reports provided by the 
HAS in their website. The reports are available from: 
• Submission: https://www.has-sante.fr/portail/jcms/c_446700/en/myozyme 
• Re-submission N°1: https://www.has-
sante.fr/portail/jcms/c_967981/en/myozyme 
• Re-submission N°2: https://www.has-
sante.fr/portail/jcms/c_1359745/en/myozyme 
• Re-submission N°3: https://www.has-
sante.fr/portail/jcms/c_2754216/fr/myozyme 
According to the Genetics Home Reference website “the Pompe disease is an inherited 
disorder caused by the build-up of a complex sugar called glycogen in the body's cells. 
The accumulation of glycogen in certain organs and tissues, especially muscles, impairs 
their ability to function normally.” 
Source : https://www.alux.com/most-
expensive-drug  
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According to the report submitted by Genzyme to the HAS there are two forms of Pompe 
disease:  
• “The classic form of infantile-onset Pompe disease begins within a few months of 
birth. Infants with this disorder typically experience muscle weakness 
(myopathy), poor muscle tone (hypotonia), an enlarged liver (hepatomegaly), and 
heart defects. Affected infants may also fail to gain weight and grow at the 
expected rate (failure to thrive) and have breathing problems. If untreated, this 
form of Pompe disease leads to death from heart failure in the first year of life.” 
• “The late-onset type of Pompe disease may not become apparent until later in 
childhood, adolescence, or adulthood. Most individuals with late-onset Pompe 
disease experience progressive muscle weakness, especially in the legs and the 
trunk, including the muscles that control breathing. As the disorder progresses, 
breathing problems can lead to respiratory failure.” 
Myozyme is a replacement therapy of the Alglucosidase Alfa enzyme. It obtained the 
market authorization in 2006 for the two clinical groups, the infantile and the late-onset. 
It is the first drug to treat this disease. The Pompe disease is a rare disease, according to 
the HAS its frequency is “one suffering person on 138 000 people”. In total nowadays, 
the target population of Myozyme is about “170 people from which around 20 are the 
infantile clinical form of the disease”. 
5.3.3.2. Submission: 
In its first submission Genzyme provided three randomized controlled trials. Two for the 
infantile form, and one for the late one. 
The main criteria of the infantile-onset studies was the survival rate while the second 
criteria were various as the growth and improvement of the cerebral capacity, the survival 
rate without respiratory aid or the decrease of the left ventricular mass. In the first study, 
the survival rate was 100% after 18 months and patients showed a clear improvement of 
their cerebral capacity. The second study got a survival rate of 73% after 52 weeks and 
similar benefits on the cerebral capacity were demonstrated. 
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The small number of patients in the late-onset clinical trial (Five patients) and the 
heterogeneity of the results didn’t allow any conclusions on the effectiveness of the drug. 
The very small number of patients in the trial is mainly due to the rarity of the Pompe 
disease. Genzyme also provided a RWE data from an observational study authorized in 
the context of an Expanded Access Program (EAP). According to the FDA (U.S Food & 
Drug Administration) an EAP, also called "compassionate use," is “the use outside of a 
clinical trial of an investigational medical product (still not approved) to patient suffering 
from a serious disease or condition for which there no other alternative therapy exists”. 
The results were also to heterogeneous to make any conclusions. 
The HAS granted the inscription on the reimbursement list for Myozyme to treat 
the infantile-onset and refused it for the late-onset because of the lack of data on the 
drug effectiveness in this clinical form. 
5.3.3.3. Re-submission: June 2010 
The re-submission focused only on the late-onset form of the disease. Genzyme delivered 
one randomized controlled trial and five RWE. 
• The randomized controlled trial vs placebo was evaluating the global physical 
capacity of the patients. Results were positives for the group treated with 
Myozyme; the 6 minutes’ walk test showed a significant improvement. Patients 
could walk on a bigger distance than the placebo group. 
• Two prospective observational studies were refused because of the small number 
of patients. Their results were took into account only for the tolerance analysis of 
the submissions. 
• An observational study studied the capacity of walking of 44 patients after a 
Myozyme treatment of one year. Results confirmed the randomized controlled 
trial. Indeed, patients could walk far longer at the end of the study. 
• The French Pompe disease registry was created in 2004. An evaluation of the 
people suffering of Pompe disease is recommended every year, and every 6 
months for patients under Myozyme treatment. On January 1st 2009, on the 75-
people included in the registry, 60 of them were under Myozyme treatment. Data 
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collected from the registry showed a quite variability among the patients. But a 
stability or an improvement of physical capacity is seen for 2/3 of the patients. 
• The international Pompe disease registry started in 2004 includes in October 2008 
564 patients from the country where Myozyme got the market authorization; 
France and USA. Data were not correctly collected along time, therefore the data 
were not accepted.  
 
For its decision HAS considered the following features: the gravity of the disease, the 
lack of alternative treatment, the low undesirable effects of Myozyme and its 
effectiveness to stabilize or improve the physical capacity of patients. HAS regretted the 
lack of data on the morbidity and on the quality of life. Moreover, data in long term are 
missing. HAS observed that the effectiveness of the treatment is limited but the 
gravity of the disease, the lack of alternative treatment and the low undesirable 
effects of Myozyme granted it on the inscription list for reimbursement. HAS gave 
a weak SMR (Service Médical Rendu – Medical benefits) which is equivalent to the 
first level of reimbursement allowing Myozyme to get a reimbursement of 15% and 
an ASMR V. 
The HAS insisted on the importance of the Pompe disease registry. They recommended 
a regular evaluation of the patients under treatment in order to be able to re-evaluate later 
the long-term effectiveness of Myozyme. 
 
5.3.3.4. Re-submission: January 2013 and March 2017 
Two other resubmissions happened in the last years in order to revaluate the SMR/ASMR 
of Myozyme to get a better price and reimbursement. New data were collected, both RCTs 
and RWE, as retrospective studies and data from the French Pompe disease registry. The 
resubmission of January 2013 was a revaluation of the effectiveness of Myozyme for the 
late-onset clinical form only. No further effectiveness effects were shown and the SMR 
remained weak and the ASMR level 1.  
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The resubmission of March 2017 also concerned the late-onset form but also the infantile 
one. The evidences were mainly clinical trials, RCTs an RWE, as retrospective studies 
and data from the registry. Long term data didn’t show good results in the late-onset 
patients. Myozyme procures good results on short term on the global physical capacity of 
the late-onset patients but in long term there are no change on the survival rate or on the 
progress of the disease. The new data didn’t change the SMR/ASMR in both indications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
5.4. Results & Conclusions  
Results of the cases are mixed in that it is impossible to conclude in any of the three cases 
that the RWE made just by itself changed the HTA decision. 
The modification of the HTA decision for a better price or/and reimbursement always 
came with at least one or more of the following elements: a discount, a Managed Entry 
Agreements or a RCT. 
Resubmission of the case 1: RWE + RCT + Discount + MEA 
Resubmission of the case 2: RWE + Discount  
Resubmission of the case 3: RWE + RCTs 
Table 5.3: Key elements which changed the HTA decision 
 Case 1: Yervoy Case 2: Zaltrap Case 3: Myozyme 
RWE    
Discount    
MEA    
RCTs    
Source: Information described above in the case studies 
In submission, it is impossible that a manufacturer brings only RWE. RCTs remain the 
gold standard. Nevertheless, in re-submission it is different. For example, in case 2 
Yervoy, no new RCT were presented. Effectiveness was already proven; the problem was 
in the economic analysis. A combination of RWE and discount succeed to change the 
HTA decision. While in submission the role of RWE is to support RCTs, it seems that in 
re-submission its role are more various: 
5.4.1. Market Access 
RWE’s role is confirmed in Managed Entry Agreements as in the case 1 of Yervoy. When 
the price of a drug is very high and the results on effectiveness were variable, there is a 
risk on the cost effectiveness of the drug. The MEA as the one of Yervoy can fill in the 
potential budget gap by paying the cost of difference in performance between the 
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observed benefits and the benefits presented in the submission. In this case RWE is the 
indicator to measure the performance and so determine the potential rebate. MEA 
combined with RWE are a key tool to improve the market access of a drug. 
5.4.2. Long-term follow-up 
RWE’s biggest advantage is its possible long duration in comparison with a RCT. When 
long-term effectiveness can’t be proven with RCTs, RWE can take over and provide some 
months or years later the pieces of long-term evidences. HAS clearly confirmed its 
interest in the disease registries in order to follow-up the long-term effectiveness of drugs 
and potentially change the price and reimbursement some years after the first submission.  
A typical strategy in Market Access Business Unit is to prepare, since the start, a drug for 
two or more indications but to obtain the reimbursement and price at different moment. 
Some indications can take more times to prove effectiveness while others show a 
particular interest to access the market first taking into consideration the competitors pipe-
lines. In this case RWE can be integrated, since the start, in the strategy of long-term 
follow-up for a specific indication which has different market access needs. 
5.4.3. QALY Calculation 
In the case 2 of Zaltrap in Scotland, the SMC said explicitly that the decrease of the price 
per QALY was mainly due to the discount than the RWE. Nevertheless, the RWE succeed 
to slightly increase the QALY gain and so contributed to the decrease of the cost per 
QALY. In cost-effectiveness model with QALY calculation RWE can weigh in the scale 
by influencing either the quantity of life gained or the quality of life improvement. The 
quantity of life gained can be proved by long-term RWE as registries while the quality of 
life can be demonstrated with surveys as the two questionnaire used in the case 2 of 
Zaltrap. 
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6. Conclusion 
This paper approached the positive impact of RWE on the HTA price and reimbursement 
submissions. The first study examined one full month of submissions from the French 
HTA (HAS) in order to measure the degree of acceptation of RWE in HTA submissions 
and the reasons why the HTAs could refuse RWE. While the second study analysed three 
cases of resubmissions where RWE did change the HTA decisions into a positive 
recommendation.  
In the first study, results showed that RWE were accepted by HAS when proving 
tolerance of the drug but refused when proving efficacy. Reasons of refusal are reflecting 
the lack of rigor of RWE and can be gathered into three groups: (1) Problem of focus 
(different population, period or geographical zone into a same study or comparing to the 
placebo group), (2) lack of information (data missing or not well described, too much 
patients dropping the study) and (3) modification of the results (existing bias, weak 
statistical power, overestimation or high variability of results). Results of the second study 
are mixed and complex, in that RWE does show a positive impact but this impact is 
limited and hard to measure. Indeed, it appeared that in the three cases RWE did not 
change the HTA decision only by itself. The modification of the HTA decision were 
always a combination of RWE with one or more of the following elements: a discount, a 
Managed Entry Agreements or a RCT. 
To the best of my knowledge, my paper is the first study to examine and collect HTAs 
reasons to refuse RWE. The results of the first study of my paper prove that RWE is not 
overcoming RCTs. The lack of rigor, already explained in the literature, is confirmed as 
the big weakness of RWE. It seems completely impossible that in the future 
manufacturers could only bring a RWE to an HTA submission. The rigor of RCTs remain 
the gold standard. Nevertheless, the three case studies showed that the impact of RWE is 
bigger in resubmission. When RCTs failed to prove a positive economic case, a long-term 
efficacy or an important efficacy risk, RWE brought, in combination with discount or 
MEA, the missing piece of evidence. These results are consistent with the article of Liden 
et al (2015) which conclusions were similar. However, my case studies are far more 
described and analysed, which is bringing to the actual literature a more complete and 
detailed picture of the impact of RWE. While the role of RWE is very often described 
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in the literature as a support to RCTs, I would rather conclude that its main 
impactful role is to fill the “evidence gap” when RCTs failed to bring it. 
As said previously, I’m convinced that RWE won’t overcome RCTs but I think that the 
role of RWE in HTA recommendations will increase. My job in a big pharma company 
in the market access division showed me that manufacturers are investing in RWE. Their 
biggest challenge is to increase the rigor of RWE by improving the reliability of the data 
and standardize the process of real world data collection. The second challenge is to 
integrate RWE in the early molecule development strategy by analysing where RCTs will 
have difficulties to bring good evidence and so prepare in advance the RWE that will fill 
the evidence gap. This early RCTs/RWE complementary strategy is not already 
implemented in pharma companies. One action to take could be to work closely with 
patient registries in order to help them to collect reliable and standardized data.  
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